首页> 美国卫生研究院文献>Thoracic Cancer >Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for extensive‐stage small cell lung cancer: A systematic review and meta‐analysis

【2h】

Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for extensive‐stage small cell lung cancer: A systematic review and meta‐analysis

机译：PD-1 / PD-L1抑制剂的功效和安全性Plus化疗与化疗单独作为一种广泛阶段小细胞肺癌的一线治疗：系统评价和荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Thoracic Cancer
作者
Shuang Zhang; Shuang Li; Ying Cheng;
展开▼
作者单位

展开▼
年(卷),期 2020(11),12
年度 2020
页码 3536–3546
总页数 11
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
First‐line treatment; immune checkpoint inhibitor; meta‐analysis; PD‐1/PD‐L1 inhibitor; small cell lung cancer;

机译：一线治疗;免疫检查点抑制剂;Meta分析;PD-1 / PD-L1抑制剂;小细胞肺癌;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for extensive‐stage small cell lung cancer: A systematic review and meta‐analysis [J] . Shuang Zhang, Shuang Li, Ying Cheng Thoracic cancer. . 2020,第12期

机译：PD-1 / PD-L1抑制剂的功效和安全性Plus化疗与化疗单独作为一种广泛阶段小细胞肺癌的一线治疗：系统评价和荟萃分析
2. Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis [J] . Khunger Monica, Jain Prantesh, Rakshit Sagar, Clinical lung cancer . 2018,第3期

机译：PD-1 / PD-L1抑制剂在治疗Naive和化疗 - 耐火患者中的安全性和有效性 - 无小细胞肺癌：系统评价和荟萃分析
3. EFFICACY AND SAFETY OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER IN ASIAN PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS [J] . Hyderboini R. K., Vsn M., Chidirala S. R., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：Bevacizumab Plus化疗与化疗在亚洲患者中非小细胞肺癌治疗中的疗效和安全性：系统审查和荟萃分析
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Subgroup analysis based on prognostic and predictive gene signatures for adjuvant chemotherapy in early-stage non-small-cell lung cancer patients [D] . Pluta, Dustin. 2015

机译：基于预后和预测基因特征的亚组分析用于早期非小细胞肺癌患者的辅助化疗
6. Comparative Efficacy and Safety of Immunotherapeutic Regimens with PD-1/PD-L1 Inhibitors for Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis [O] . Koichi Ando, Ryo Manabe, Yasunari Kishino, 2021

机译：PD-1 / Pd-L1抑制剂对先前未处理的广泛阶段小细胞肺癌的比较疗效和安全性的对比疗效和安全性：系统综述和网络荟萃分析
7. Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for extensive‐stage small cell lung cancer: A systematic review and meta‐analysis [O] . Shuang Zhang, Shuang Li, Ying Cheng 2020

机译：PD-1 / PD-L1抑制剂的功效和安全性Plus化疗与化疗单独作为一种广泛阶段小细胞肺癌的一线治疗：系统评价和荟萃分析

Efficacy and safety of PD‐1/PD‐L1 inhibitor plus chemotherapy versus chemotherapy alone as first‐line treatment for extensive‐stage small cell lung cancer: A systematic review and meta‐analysis

著录项

引文网络

相似文献

相关主题

期刊订阅